CA-RESMED
15.10.2018 15:07:12 CEST | Business Wire | Press release
ResMed (NYSE: RMD, ASX: RMD) today announced the availability of its first minimal-contact full face CPAP mask, AirFit F30, the latest addition to its AirFit mask portfolio, which helps sleep apnea patients reduce facial marks, wear glasses in bed and curl up closer to their bed partner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005185/en/
Availability
AirFit F30 is available for sale now in the United States and Canada, and will be on display at the Medtrade Fall conference this week in Atlanta; visit ResMed’s Booth #2116.
AirFit F30 fits 93 percent of patients,1 and features a minimal-contact cushion that sits just below the nose, preventing top-of-the-nose red marks and irritation, plus reducing feelings of claustrophobia for some full face wearers. It also has ResMed’s QuietAir vent, making the mask quieter than ambient noise in the bedroom.
New claims: ResMed AirFit F30 vs. the competition
Nearly 2 to 1 patients preferred AirFit F30 over the current market leader in minimal-contact full face masks.2 When specifically asked about comfort, seal and ease of use, more patients picked AirFit F30 each time.2 AirFit F30 is also quieter than the current market leader, based on published performance (21 vs. 24 dBA),3 with fewer sleep disruptions reported due to airflow.2
“AirFit F30 is a clear choice over other minimal-contact full face masks,” said Jim Hollingshead, president of ResMed’s Sleep business. “We’re excited to now offer it, along with the rest of our full face, nasal and nasal pillows options, for an easy, comfortable, stable fit and a great night’s sleep.”
About ResMed
ResMed (NYSE: RMD, ASX: RMD), a world-leading connected health company with more than 6 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com
1 ResMed AirFit F30 fitting study of 75 patients conducted from April to
May 2018 in multiple U.S. locations.
2 ResMed AirFit F30 guided
clinical study of 23 patients conducted from June 8 to August 24 2018 in
Australia. Study tested ResMed AirFit F30 against Phillips Respironics
DreamWear full face (both masks are minimal-contact, full face).
3
ResMed AirFit user guide, 2018. Philips Respironics DreamWear full face
mask instructions for use, 2016.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181015005185/en/
Contact:
ResMed For media: Jayme Rubenstein +1 858.836.6798 news@resmed.com or For investors: Amy Wakeham +1 858.836.5000 investorrelations@resmed.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JTB to Acquire Asian DMC Leader EXO Travel for Accelerated Global Growth18.6.2026 04:00:00 CEST | Press release
— Advancing JTB's “Departing Globally, Arriving Globally” Vision — JTB Corp. today announced that it has reached an agreement to acquire all the shares of All Wise Holdings Pte. Ltd., the operator of Bangkok-based EXO Travel Group, a leading Destination Management Companies (DMCs) in Asia. The acquisition will be made through a JTB group company in the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106801/en/ EXO Travel operates in the B2B market, primarily across Asia Pacific. For over 30 years, it has consistently maintained high customer satisfaction based on trust, achievements and high-quality service. The company has a strong brand presence in the affluent markets of Europe, North America and Australia, where the trust of partner companies contributes significantly to its value. Additionally, EXO Travel leverages its extensive network of destinations in Asia Pacific to develop strong products
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 01:01:00 CEST | Press release
The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform,EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit million clinical, regulatory, and commercial milestones, along with royalties on net sales LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together,
Joe Vernachio Named President of SOREL18.6.2026 00:00:00 CEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 22:30:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa
Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 22:05:00 CEST | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom